Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities: 2016-2024

Historic Cash from Financing Activities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $1.0 billion.

  • Crinetics Pharmaceuticals' Cash from Financing Activities fell 94.62% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.6 million, marking a year-over-year increase of 14.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 159.79% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Cash from Financing Activities is $1.0 billion, which was up 159.79% from $388.9 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Cash from Financing Activities high stood at $1.0 billion for FY2024, and its period low was $114.6 million during FY2020.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Cash from Financing Activities value was $388.9 million (recorded in 2023), while the average stood at $507.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 170,901.49% in 2020, then slumped by 51.73% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $114.6 million in 2020, then skyrocketed by 120.54% to $252.7 million in 2021, then slumped by 51.73% to $122.0 million in 2022, then soared by 218.90% to $388.9 million in 2023, then skyrocketed by 159.79% to $1.0 billion in 2024.